Once its full clinical potential has been realized, hematopoietic stem cell (HSC)-based gene therapy (GT) promises to cure a wide array of both inborn and acquired diseases. For many genetic disorders, early onset and irreparable tissue and organ damage necessitate innovative methods that allow therapeutic intervention early in development if a full cure is to be realized. Performing GT in utero would allow early correction prior to disease onset, and is thus one of the few therapeutic modalities that could promise the birth of a healthy infant. Several features of the developing fetus may circumvent obstacles that have thus far been observed in GT trials. For example, the immune naivete of the early gestational fetus may evade immune reactions to the vector and transgene product. Furthermore, fetal exposure to foreign antigens can result in sustained tolerance, suggesting that induction of tolerance to the vector/transgene product could allow postnatal treatment to be performed successfully. In addition to these immunologic advantages, the fetal hematopoietic system promises to be more amenable to retroviral-mediated gene transfer than either the neonate or adult as a result of both the proliferation and expansion of the stem/progenitor cell pool that take place during fetal development. To investigate whether these characteristics of the developing fetus could be used to advantage to efficiently transduce HSC, we developed an approach to in utero GT in which retroviral vectors were injected intraperitoneally into fetal sheep. This approach resulted in the transfer and long-term (>5 years) expression of exogenous genes at relatively low levels within the hematopoietic system of primary and secondary recipients. The overall goal of the proposed studies is to achieve therapeutic levels of gene transfer/expression in HSC following direct injection of retroviral vectors in utero. We will also evaluate safety issues that our previous studies suggested might arise from this approach, including vector distribution, fetal germline involvement, and maternal transfer. We will employ the well characterized clinically relevant fetal sheep model to: 1) determine the most efficient method for gene transfer into fetal HSC by comparing recipient gestational age, number of vector injections, and supernatant versus producer cells; 2) evaluate whether vector tissue distribution, potential for germline alteration, and maternal transfer are influenced by the conditions described in Aim #1; 3) examine whether tolerance to the vector/transgene is induced following gene transfer during the period of pre-immunity, and whether this permits post-natal """"""""boosting"""""""" by administering vector or transduced autologous cells without eliciting an immune response. The proposed studies will provide essential information about efficiently transferring exogenous genes to fetal HSC in utero while minimizing the potential fetal/maternal risks. These studies in this unique fetal model may lay the groundwork for devising clinically relevant in itero GT approaches for treating a variety of genetic diseases in human fetuses early in gestation, prior to disease onset.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD043038-04
Application #
6863627
Study Section
Hematology Subcommittee 2 (HEM)
Program Officer
Oster-Granite, Mary Lou
Project Start
2002-03-01
Project End
2007-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
4
Fiscal Year
2005
Total Cost
$195,750
Indirect Cost
Name
University of Nevada Reno
Department
Veterinary Sciences
Type
Schools of Earth Sciences/Natur
DUNS #
146515460
City
Reno
State
NV
Country
United States
Zip Code
89557
Ross, Christina L; Siriwardane, Mevan; Almeida-Porada, Graça et al. (2015) The effect of low-frequency electromagnetic field on human bone marrow stem/progenitor cell differentiation. Stem Cell Res 15:96-108
Tellez, Joseph; Van Vliet, Kim; Tseng, Yu-Shan et al. (2013) Characterization of naturally-occurring humoral immunity to AAV in sheep. PLoS One 8:e75142
Ozturk, Ferhat; Park, Paul J; Tellez, Joseph et al. (2012) Expression levels of the PiT-2 receptor explain, in part, the gestational age-dependent alterations in transduction efficiency after in utero retroviral-mediated gene transfer. J Gene Med 14:169-81
Porada, Christopher D; Almeida-Porada, Graça (2010) Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev 62:1156-66
Park, Paul J; Colletti, Evan; Ozturk, Ferhat et al. (2009) Factors determining the risk of inadvertent retroviral transduction of male germ cells after in utero gene transfer in sheep. Hum Gene Ther 20:201-15
Porada, Christopher D; Harrison-Findik, Duygu D; Sanada, Chad et al. (2008) Development and characterization of a novel CD34 monoclonal antibody that identifies sheep hematopoietic stem/progenitor cells. Exp Hematol 36:1739-49
Colletti, Evan; Lindstedt, Sean; Park, Paul J et al. (2008) Early fetal gene delivery utilizes both central and peripheral mechanisms of tolerance induction. Exp Hematol 36:816-22
Porada, Christopher D; Park, Paul J; Tellez, Joe et al. (2005) Male germ-line cells are at risk following direct-injection retroviral-mediated gene transfer in utero. Mol Ther 12:754-62
Porada, Christopher D; Park, Paul J; Almeida-Porada, Graca et al. (2005) Gestational age of recipient determines pattern and level of transgene expression following in utero retroviral gene transfer. Mol Ther 11:284-93
Lucas, M Lee; Seidel, Nancy E; Porada, Christopher D et al. (2005) Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes. Blood 106:51-8